Biotech · Public company · Boston, MA, US
Praxis Precision Medicines, Inc.
Ticker PRAX · SEC CIK 0001689548
Track this companyFree. Adds Praxis Precision Medicines, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials168 recruiting or active
Pipeline programs29From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline29
- 0.5mg elsunersenPhase 3 · Epileptic EncephalopathyClinicalTrials.gov · fetched Nov 12, 2026
- 1.0mg/kg/day PRAX-562Phase 3 · Developmental and Epileptic Encephalopathy 1ClinicalTrials.gov · fetched Nov 12, 2026
- 1.5mg/kg/day PRAX-562Phase 3 · Developmental and Epileptic Encephalopathy 1ClinicalTrials.gov · fetched Nov 12, 2026
- 1mg elsunersenPhase 3 · Epileptic EncephalopathyClinicalTrials.gov · fetched Nov 12, 2026
- 20 mg/day vormatrogine for 12 weeksPhase 3 · Focal EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeksPhase 3 · Focal SeizureClinicalTrials.gov · fetched Nov 12, 2026
- 30 mg/day vormatrogine for 12 weeksPhase 3 · Focal EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- 40 mg/day vormatrogine for 12 weeksPhase 3 · Focal EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- 60 mg ulixacaltamidePhase 3 · Essential TremorClinicalTrials.gov · fetched Nov 12, 2026
- PRAX-114Phase 3 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- PRAX-562Phase 3 · SCN2A EncephalopathyClinicalTrials.gov · fetched Nov 12, 2026
- vormatroginePhase 3 · Epilepsy, Tonic-ClonicClinicalTrials.gov · fetched Nov 12, 2026
- 10 mg PRAX-114Phase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- 10 mg PRAX-114 or 20 mg PRAX-114Phase 2 · Essential TremorClinicalTrials.gov · fetched Nov 12, 2026
- 100 mg PRAX-944Phase 2 · Essential TremorClinicalTrials.gov · fetched Nov 12, 2026
- 20 mg PRAX-114Phase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- 30mg PRAX-628Phase 2 · Focal Onset SeizureClinicalTrials.gov · fetched Nov 12, 2026
- 40 mg PRAX-114Phase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- 40 mg PRAX-114Phase 2 · Post-traumatic Stress DisorderClinicalTrials.gov · fetched Nov 12, 2026
- 60 mg PRAX-114Phase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- 60 mg PRAX-114 or 40 mg PRAX-114Phase 2 · Post-traumatic Stress DisorderClinicalTrials.gov · fetched Nov 12, 2026
- 60 mg PRAX-944Phase 2 · Essential TremorClinicalTrials.gov · fetched Nov 12, 2026
- Flexibly dosed 20 mg to 100 mg PRAX-944Phase 2 · Essential TremorClinicalTrials.gov · fetched Nov 12, 2026
- Part A: 20 and 40 mg PRAX-944Phase 2 · Essential TremorClinicalTrials.gov · fetched Nov 12, 2026
- Part B: 120 mg PRAX-944Phase 2 · Essential TremorClinicalTrials.gov · fetched Nov 12, 2026
- PRAX-222 - Fixed DosesPhase 2 · SCN2A-DEEClinicalTrials.gov · fetched Nov 12, 2026
- PRAX-222 - Initial Ascending DosesPhase 2 · SCN2A-DEEClinicalTrials.gov · fetched Nov 12, 2026
- PRAX-222 - Initial DosePhase 2 · SCN2A-DEEClinicalTrials.gov · fetched Nov 12, 2026
- PRAX-222 - Optional Ascending DosesPhase 2 · SCN2A-DEEClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials16
- Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal SeizuresPHASE3 · ACTIVE_NOT_RECRUITING · started Jan 29, 2026ClinicalTrials.gov NCT07505004 · fetched Nov 12, 2026
- Clinical Trial of Vormatrigine in Adult Patients With EpilepsyPHASE3 · ENROLLING_BY_INVITATION · started Oct 27, 2025ClinicalTrials.gov NCT07287163 · fetched Nov 12, 2026
- A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyPHASE3 · RECRUITING · started Aug 13, 2025ClinicalTrials.gov NCT07019922 · fetched Nov 12, 2026
- A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutriginePHASE3 · ACTIVE_NOT_RECRUITING · started Jul 9, 2025ClinicalTrials.gov NCT07010471 · fetched Nov 12, 2026
- An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic SeizuresPHASE2 · RECRUITING · started Jan 10, 2025ClinicalTrials.gov NCT06908356 · fetched Nov 12, 2026
- Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)PHASE2_PHASE3 · COMPLETED · started Dec 11, 2024ClinicalTrials.gov NCT06999902 · fetched Nov 12, 2026
- Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)PHASE3 · RECRUITING · started Nov 2, 2023ClinicalTrials.gov NCT06087276 · fetched Nov 12, 2026
- A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Aug 2, 2023ClinicalTrials.gov NCT05818553 · fetched Nov 12, 2026
- A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic EncephalopathyPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 13, 2023ClinicalTrials.gov NCT05737784 · fetched Nov 12, 2026
- A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic EncephalopathyCOMPLETED · started Apr 15, 2022ClinicalTrials.gov NCT05407727 · fetched Nov 12, 2026
- A Clinical Trial of PRAX-114 in Participants With Essential TremorPHASE2 · WITHDRAWN · started Apr 5, 2022ClinicalTrials.gov NCT05387642 · fetched Nov 12, 2026
- A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress DisorderPHASE2 · TERMINATED · started Jan 25, 2022ClinicalTrials.gov NCT05260541 · fetched Nov 12, 2026
- A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential TremorPHASE2 · COMPLETED · started Oct 14, 2021ClinicalTrials.gov NCT05021991 · fetched Nov 12, 2026
- A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive DisorderPHASE2 · COMPLETED · started Jun 24, 2021ClinicalTrials.gov NCT04969510 · fetched Nov 12, 2026
- A Clinical Trial of PRAX-114 in Participants With Major Depressive DisorderPHASE2_PHASE3 · COMPLETED · started Mar 30, 2021ClinicalTrials.gov NCT04832425 · fetched Nov 12, 2026
- A Clinical Trial of PRAX-944 in Participants With Essential TremorPHASE2 · COMPLETED · started Mar 3, 2020ClinicalTrials.gov NCT05021978 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 7, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 1, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026